Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.84 |
| ▸ | TP53 | P04637 | 4/20 | 0.71 |
| ▸ | THRB | P10828 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24619236 | 0.92 | MAPT (0.71) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL30086042 | 0.92 | MAPT (0.71) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL23493856 | 0.92 | MAPT (1.00) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL24740974 | 0.87 | MAPT (0.65) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL24105974 | 0.86 | MAPT (0.73) | MAPTTP53THRBPOLBSMN1; SMN2 | |
| SCHEMBL23493855 | 0.85 | MAPT (0.87) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL31307808 | 0.85 | MAPT (0.87) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL30085964 | 0.85 | MAPT (0.84) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL24741002 | 0.85 | MAPT (0.84) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL24619393 | 0.84 | LMNA (0.80) | MAPTTP53THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559518-B2 | Endoplasmic reticulum stress regulator comprising benzothiazoimidazolyl compound | ER STRESS RESEARCH INSTITUTE, INC. (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20210386715-A1 | ENDOPLASMIC RETICULUM STRESS REGULATOR COMPRISING BENZOTHIAZOIMIDAZOLYL COMPOUND | ER STRESS RESEARCH INSTITUTE, INC. (JP) | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559518-B2 | Endoplasmic reticulum stress regulator comprising benzothiazoimidazolyl compound | HSPA5, DNAJC10, ERP44 | MAPT 3116/4885TP53 1281/4885THRB 1454/4885 |
| US-20210386715-A1 | ENDOPLASMIC RETICULUM STRESS REGULATOR COMPRISING BENZOTHIAZOIMIDAZOLYL COMPOUND | DNAJC10, HSPA5, ERP44 | MAPT 3271/4885TP53 1668/4885THRB 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.